For healthcare professionals only
GP Notebook

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​

Downloadable resources

This drag-and-drop game will help refresh your memory on the Summary of Product Characteristics dosing recommendations for each DPP-4 inhibitor. (For HCPs in Great Britain and Northern Ireland only).

By clicking below, you will be redirected to a Boehringer Ingelheim webpage.

Patient resources

Supporting your patients during Ramadan

  • This leaflet, designed for patients, outlines the key considerations a person with diabetes should be aware of when planning to fast during Ramadan

 

Ramadan fasting: A guide for adults with type 2 diabetes

  • The importance of a pre-Ramadan medication review
  • When a person with diabetes should break their Ramadan fast
  • Diet and exercise advice

Webinar

Sarah Jarvis

Kevin Fernando

The event starts in:

DAYS
HRS
MIN
SEC

Coming soon

Join our faculty as they discuss the role of clinical inertia in the suboptimal achievement of treatment targets and share practical tips for addressing this topic with your adult type 2 diabetes patients

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

PC-GB-107280 V7 | February 2024

This website is for healthcare professionals in Great Britain, Northern Ireland and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in Great Britain, Northern Ireland or the Republic of Ireland by clicking below.

You are leaving this site.

You are now leaving https://dev.resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.